JP2014521641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521641A5 JP2014521641A5 JP2014522802A JP2014522802A JP2014521641A5 JP 2014521641 A5 JP2014521641 A5 JP 2014521641A5 JP 2014522802 A JP2014522802 A JP 2014522802A JP 2014522802 A JP2014522802 A JP 2014522802A JP 2014521641 A5 JP2014521641 A5 JP 2014521641A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- amphetamine
- salt
- prodrug
- homoarginine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims description 70
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 62
- 229940025084 amphetamine Drugs 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 51
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 claims description 48
- 239000000651 prodrug Substances 0.000 claims description 38
- 229940002612 prodrug Drugs 0.000 claims description 38
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 claims description 24
- -1 homoarginine amphetamine derivative Chemical class 0.000 claims description 24
- 239000012458 free base Substances 0.000 claims description 22
- 230000000694 effects Effects 0.000 claims description 16
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 12
- 238000011002 quantification Methods 0.000 claims description 12
- 239000010409 thin film Substances 0.000 claims description 12
- 241000282412 Homo Species 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 6
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 239000002269 analeptic agent Substances 0.000 claims description 2
- 239000003368 psychostimulant agent Substances 0.000 claims description 2
- 239000000021 stimulant Substances 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/045954 WO2013019187A1 (en) | 2011-07-29 | 2011-07-29 | Homoarginine prodrugs and/or conjugates of amphetamine and other stimulants and processes for making and using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014521641A JP2014521641A (ja) | 2014-08-28 |
| JP2014521641A5 true JP2014521641A5 (enExample) | 2014-10-09 |
Family
ID=47629539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014522802A Pending JP2014521641A (ja) | 2011-07-29 | 2011-07-29 | ホモアルギニンプロドラッグおよび／またはアンフェタミンおよび他の興奮剤の抱合体、ならびに同物を作製および使用するためのプロセス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140171510A1 (enExample) |
| EP (1) | EP2739140A4 (enExample) |
| JP (1) | JP2014521641A (enExample) |
| AU (1) | AU2011374269A1 (enExample) |
| CA (1) | CA2843390A1 (enExample) |
| WO (1) | WO2013019187A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014144115A1 (en) * | 2013-03-15 | 2014-09-18 | Shire Llc | Fixed dose combination treatment for schizophrenia |
| MX389336B (es) | 2016-11-15 | 2025-03-20 | Klaria Pharma Holding Ab | Formulacion farmaceutica. |
| JP2020516694A (ja) * | 2017-04-10 | 2020-06-11 | シャイアー ファーマシューティカルズ インコーポレイテッドＳｈｉｒｅ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | アンフェタミンプロドラッグを使用する治療方法 |
| GB201709141D0 (en) | 2017-06-08 | 2017-07-26 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
| CA3081841A1 (en) * | 2017-11-30 | 2019-06-06 | SpecGx LLC | Process for preparing acylated amphetamine derivatives |
| WO2019136224A1 (en) * | 2018-01-05 | 2019-07-11 | Shire Human Genetic Therapies, Inc. | Amphetamine-guanfacine combinations for treatment of neuropsychiatric disorders |
| WO2019199731A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals Inc. | Amphetamine prodrug and crystalline froms thereof |
| WO2019199724A1 (en) * | 2018-04-10 | 2019-10-17 | Shire Pharmaceuticals, Inc. | Salts of amphetamine-homoarginine conjugate prodrug |
| GB201808462D0 (en) * | 2018-05-23 | 2018-07-11 | Klaria Pharma Holding Ab | Pharmaceutical formulation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772222B2 (en) * | 2007-02-08 | 2010-08-10 | Mickle Travis C | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
| CN101594778A (zh) * | 2006-12-11 | 2009-12-02 | 凯姆制药公司 | 苯丙胺的非标准氨基酸结合物及其制备和使用的方法 |
-
2011
- 2011-07-29 JP JP2014522802A patent/JP2014521641A/ja active Pending
- 2011-07-29 WO PCT/US2011/045954 patent/WO2013019187A1/en not_active Ceased
- 2011-07-29 CA CA 2843390 patent/CA2843390A1/en not_active Abandoned
- 2011-07-29 AU AU2011374269A patent/AU2011374269A1/en not_active Abandoned
- 2011-07-29 US US14/235,743 patent/US20140171510A1/en not_active Abandoned
- 2011-07-29 EP EP11870434.5A patent/EP2739140A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521641A5 (enExample) | ||
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
| IL314360A (en) | Method of synthesizing thyroid hormone analogs and polymorphs thereof | |
| JP2013528600A5 (enExample) | ||
| JP2013513612A5 (enExample) | ||
| JP2012517449A5 (enExample) | ||
| JP2014503560A5 (enExample) | ||
| JP2012530723A5 (enExample) | ||
| JP2019517587A5 (enExample) | ||
| JP2017508817A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| ECSP10010052A (es) | Formulaciones galenicas de alisquireno y valsartan | |
| JP2013516493A5 (enExample) | ||
| JP2020533296A5 (enExample) | ||
| JP2018531273A5 (enExample) | ||
| Paccaly et al. | Absence of clinically relevant drug interaction between delamanid, a new drug for multidrug-resistant tuberculosis (MDR-TB) and tenofovir or lopinavir/ritonavir in healthy subjects | |
| JP2018506533A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2013536206A5 (enExample) | ||
| JP2018512451A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| IL272834B2 (en) | Amantadine compositions, preparations thereof, and methods of use | |
| JP2019531286A5 (enExample) | ||
| JP2019509309A5 (enExample) |